Prognostic DNA methylation markers for prostate cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Diagnostics

Background:

• Prostate cancer (PC) is a leading cause of cancer death in men, characterized by significant clinical heterogeneity.
• Accurate prediction of tumor aggressiveness at diagnosis remains a challenge, necessitating novel prognostic tools.
• Epigenetic alterations, particularly DNA methylation, are implicated in PC initiation and progression.

Purpose of the Study:

• To review the current evidence on the prognostic potential of DNA methylation biomarkers for prostate cancer.
• To highlight promising methylation marker candidates for predicting PC tumor progression.
• To address the urgent need for improved biomarkers in PC management.

Main Methods:

• Literature review of studies investigating DNA methylation markers in prostate cancer prognosis.
• Analysis of evidence supporting the prognostic value of specific methylation markers and signatures.
• Evaluation of clinical validation and conflicting evidence for identified biomarker candidates.

Main Results:

• DNA methylation is a frequently studied epigenetic alteration in PC with demonstrated prognostic potential.
• Promising candidates include PITX2, C1orf114 (CCDC181), the GABRE~miR-452~miR-224 locus, and the AOX1/C1orf114/HAPLN3 signature.
• Other investigated markers show less stringent validation or conflicting prognostic evidence.

Conclusions:

• DNA methylation biomarkers hold significant prognostic potential for prostate cancer.
• Further validation is needed for the most promising candidates to aid in clinical decision-making.
• These epigenetic markers could improve the distinction between aggressive and indolent PC.